These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 24685380)
41. Implantable cardioverter defibrillator as therapeutic option for sudden cardiac death secondary to severe coronary vasospasm. Fuertes J; Gallego P; Peinado R; Merino JL Int J Cardiol; 1998 Jan; 63(2):181-3. PubMed ID: 9510493 [TBL] [Abstract][Full Text] [Related]
42. Saving lives and reducing inappropriate device therapy: the MADIT family of implantable cardioverter-defibrillator and cardiac resynchronization therapy trials. Moss AJ Cardiol J; 2013; 20(3):217-9. PubMed ID: 23788293 [No Abstract] [Full Text] [Related]
43. [Recovered sudden cardiac death associated with an early repolarization syndrome: case analysis and pratical aspects]. Amara W; Monsel F; Salih H; Ben Youssef I; Sergent J Ann Cardiol Angeiol (Paris); 2012 Nov; 61(5):379-81. PubMed ID: 22964083 [TBL] [Abstract][Full Text] [Related]
44. [Nursing care for automatic implantable defibrillators]. Pépin A; Samuel B; Kihel A Soins; 2006; (702 Suppl):S3-5. PubMed ID: 16493932 [No Abstract] [Full Text] [Related]
45. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations). Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697 [TBL] [Abstract][Full Text] [Related]
46. Hypertrophic cardiomyopathy with midcavitary obstruction: another substrate for ventricular tachycardia? Gerstenfeld EP J Cardiovasc Electrophysiol; 2010 Sep; 21(9):1000-1. PubMed ID: 20487115 [No Abstract] [Full Text] [Related]
47. Sudden cardiac arrest in a young patient with hypertrophic cardiomyopathy and zero canonical risk factors: the inherent limitations of risk stratification in hypertrophic cardiomyopathy. Kohorst JJ; Bos JM; Hagler DJ; Ackerman MJ Congenit Heart Dis; 2014; 9(2):E51-7. PubMed ID: 23648018 [TBL] [Abstract][Full Text] [Related]
48. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation. Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943 [TBL] [Abstract][Full Text] [Related]
49. Decline of defibrillation testing in the clinical practice: an 8-year nation-wide assessment. Brignole M; Occhetta E; Grazia Bongiorni M; Proclemer A; Favale S; Gasparini M; Accardi F; Valsecchi S Europace; 2014 Aug; 16(8):1103-4. PubMed ID: 24895021 [No Abstract] [Full Text] [Related]
50. Late implantation of an implantable cardioverter-defibrillator in a patient with Brugada syndrome prevented sudden arrhythmic death. Mok NS; Chan NY; Choi YC Int J Cardiol; 2003 Feb; 87(2-3):269-71. PubMed ID: 12559549 [No Abstract] [Full Text] [Related]
51. Public Access Defibrillation Programs: Improving Outcomes Worldwide. Valdes SO J Am Heart Assoc; 2015 Oct; 4(10):e002631. PubMed ID: 26494520 [No Abstract] [Full Text] [Related]
52. Fatal undersensing of ventricular fibrillation due to intermittent high-amplitude R waves. Anguera I; Sabaté X; Sugrañes G; Cequier A Pacing Clin Electrophysiol; 2012 Sep; 35(9):e284-6. PubMed ID: 22188442 [TBL] [Abstract][Full Text] [Related]
54. Inappropriate shock from a subcutaneous implantable cardioverter-defibrillator due to transcutaneous electrical nerve stimulation. Miller MA; Palaniswamy C; Sharma D; Reddy VY Heart Rhythm; 2015 Jul; 12(7):1702-3. PubMed ID: 25889810 [No Abstract] [Full Text] [Related]
55. MY APPROACH to Commotio Cordis. Estes NAM; Weinstock J Trends Cardiovasc Med; 2019 May; 29(4):248. PubMed ID: 30878295 [No Abstract] [Full Text] [Related]
56. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy. Li CH; Lin YJ; Huang JL; Wu TJ; Cheng CC; Lin WS; Tuan TC; Chang SL; Lo LW; Hu YF; Chao TF; Chung FP; Tsai CF; Tsao HM; Chen SA J Cardiovasc Electrophysiol; 2012 Jul; 23(7):750-6. PubMed ID: 22353378 [TBL] [Abstract][Full Text] [Related]
57. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon. Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624 [TBL] [Abstract][Full Text] [Related]